Loading…
Getting back at nature: understanding thymic development and overcoming its atrophy
T cell development is a complex and tightly regulated process involving reciprocal interactions between the thymic stroma and differentiating thymocytes. Normal thymic function is critical for immunity and microenvironmental defects predispose to dysregulation in the T cell compartment. Thymic struc...
Saved in:
Published in: | Current opinion in pharmacology 2010-08, Vol.10 (4), p.425-433 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c476t-fed0ee6655b0532f55072921353a7499065f34bba21bd84ea93c30573a347d8e3 |
---|---|
cites | |
container_end_page | 433 |
container_issue | 4 |
container_start_page | 425 |
container_title | Current opinion in pharmacology |
container_volume | 10 |
creator | Heng, Tracy SP Chidgey, Ann P Boyd, Richard L |
description | T cell development is a complex and tightly regulated process involving reciprocal interactions between the thymic stroma and differentiating thymocytes. Normal thymic function is critical for immunity and microenvironmental defects predispose to dysregulation in the T cell compartment. Thymic structure and function are also severely damaged by chemotherapy and pre-transplant conditioning. Furthermore, poor immune competence with ageing is closely linked to thymic atrophy. Overcoming such thymic defects would have immediate application in many diseases, especially the recovery of cancer patients from cytotoxic treatment. Reversing the thymus ageing process via inhibition of atrophic factors such as sex steroids or administration of thymopoietic growth factors is one possible approach. Moreover, it is becoming clear a common thymic epithelial progenitor exists, raising the possibility for de novo thymus generation using emerging stem cell and tissue engineering technologies. Achievement of this goal will open up many avenues for the application of thymus-based immune rejuvenation and manipulation. |
doi_str_mv | 10.1016/j.coph.2010.04.006 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_748935358</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1471489210000421</els_id><sourcerecordid>748935358</sourcerecordid><originalsourceid>FETCH-LOGICAL-c476t-fed0ee6655b0532f55072921353a7499065f34bba21bd84ea93c30573a347d8e3</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS0EoqXwBTig3DjtdvwvThBCQhW0SJU4FM6WY0-ot4m92M5K--1xtC0HDvhiy_Pe08xvCHlLYUuBtpe7rY37-y2D-gFiC9A-I-dUKLoRveLPn95dz87Iq5x3AFRyrl6SMwai423LzsndNZbiw69mMPahMaUJpiwJPzRLcJhyMcGt1XJ_nL1tHB5wivsZQ2lqpYkHTDbOq8KXXO2pNnR8TV6MZsr45vG-ID-_fvlxdbO5_X797erz7cYK1ZbNiA4Q21bKASRno5SgWM8ol9wo0ffQypGLYTCMDq4TaHpuOUjFDRfKdcgvyPtT7j7F3wvmomefLU6TCRiXrFUdvYbJrirZSWlTzDnhqPfJzyYdNQW9stQ7vbLUK0sNQleW1fTuMX4ZZnR_LU_wquDjSYB1yIPHpLP1GCw6n9AW7aL_f_6nf-x28sFbMz3gEfMuLilUfJrqzDTou3Wb6zIp1CMqpz-tQJoM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>748935358</pqid></control><display><type>article</type><title>Getting back at nature: understanding thymic development and overcoming its atrophy</title><source>Elsevier</source><creator>Heng, Tracy SP ; Chidgey, Ann P ; Boyd, Richard L</creator><creatorcontrib>Heng, Tracy SP ; Chidgey, Ann P ; Boyd, Richard L</creatorcontrib><description>T cell development is a complex and tightly regulated process involving reciprocal interactions between the thymic stroma and differentiating thymocytes. Normal thymic function is critical for immunity and microenvironmental defects predispose to dysregulation in the T cell compartment. Thymic structure and function are also severely damaged by chemotherapy and pre-transplant conditioning. Furthermore, poor immune competence with ageing is closely linked to thymic atrophy. Overcoming such thymic defects would have immediate application in many diseases, especially the recovery of cancer patients from cytotoxic treatment. Reversing the thymus ageing process via inhibition of atrophic factors such as sex steroids or administration of thymopoietic growth factors is one possible approach. Moreover, it is becoming clear a common thymic epithelial progenitor exists, raising the possibility for de novo thymus generation using emerging stem cell and tissue engineering technologies. Achievement of this goal will open up many avenues for the application of thymus-based immune rejuvenation and manipulation.</description><identifier>ISSN: 1471-4892</identifier><identifier>EISSN: 1471-4973</identifier><identifier>DOI: 10.1016/j.coph.2010.04.006</identifier><identifier>PMID: 20483662</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Aging - immunology ; Aging - physiology ; Animals ; Antineoplastic Agents - toxicity ; Atrophy - chemically induced ; Epithelial Cells ; Fibroblast Growth Factor 7 - pharmacology ; fms-Like Tyrosine Kinase 3 - metabolism ; Gonadal Steroid Hormones - antagonists & inhibitors ; Growth Hormone - pharmacology ; Humans ; Insulin-Like Growth Factor I - pharmacology ; Interleukin-7 - pharmacology ; Internal Medicine ; Medical Education ; Membrane Proteins - pharmacology ; Stem Cells - physiology ; Stromal Cells ; T-Lymphocytes - drug effects ; T-Lymphocytes - immunology ; T-Lymphocytes - physiology ; Thymus Gland - drug effects ; Thymus Gland - immunology ; Thymus Gland - physiology</subject><ispartof>Current opinion in pharmacology, 2010-08, Vol.10 (4), p.425-433</ispartof><rights>Elsevier Ltd</rights><rights>2010 Elsevier Ltd</rights><rights>Copyright 2010 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c476t-fed0ee6655b0532f55072921353a7499065f34bba21bd84ea93c30573a347d8e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20483662$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Heng, Tracy SP</creatorcontrib><creatorcontrib>Chidgey, Ann P</creatorcontrib><creatorcontrib>Boyd, Richard L</creatorcontrib><title>Getting back at nature: understanding thymic development and overcoming its atrophy</title><title>Current opinion in pharmacology</title><addtitle>Curr Opin Pharmacol</addtitle><description>T cell development is a complex and tightly regulated process involving reciprocal interactions between the thymic stroma and differentiating thymocytes. Normal thymic function is critical for immunity and microenvironmental defects predispose to dysregulation in the T cell compartment. Thymic structure and function are also severely damaged by chemotherapy and pre-transplant conditioning. Furthermore, poor immune competence with ageing is closely linked to thymic atrophy. Overcoming such thymic defects would have immediate application in many diseases, especially the recovery of cancer patients from cytotoxic treatment. Reversing the thymus ageing process via inhibition of atrophic factors such as sex steroids or administration of thymopoietic growth factors is one possible approach. Moreover, it is becoming clear a common thymic epithelial progenitor exists, raising the possibility for de novo thymus generation using emerging stem cell and tissue engineering technologies. Achievement of this goal will open up many avenues for the application of thymus-based immune rejuvenation and manipulation.</description><subject>Aging - immunology</subject><subject>Aging - physiology</subject><subject>Animals</subject><subject>Antineoplastic Agents - toxicity</subject><subject>Atrophy - chemically induced</subject><subject>Epithelial Cells</subject><subject>Fibroblast Growth Factor 7 - pharmacology</subject><subject>fms-Like Tyrosine Kinase 3 - metabolism</subject><subject>Gonadal Steroid Hormones - antagonists & inhibitors</subject><subject>Growth Hormone - pharmacology</subject><subject>Humans</subject><subject>Insulin-Like Growth Factor I - pharmacology</subject><subject>Interleukin-7 - pharmacology</subject><subject>Internal Medicine</subject><subject>Medical Education</subject><subject>Membrane Proteins - pharmacology</subject><subject>Stem Cells - physiology</subject><subject>Stromal Cells</subject><subject>T-Lymphocytes - drug effects</subject><subject>T-Lymphocytes - immunology</subject><subject>T-Lymphocytes - physiology</subject><subject>Thymus Gland - drug effects</subject><subject>Thymus Gland - immunology</subject><subject>Thymus Gland - physiology</subject><issn>1471-4892</issn><issn>1471-4973</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNp9kU9v1DAQxS0EoqXwBTig3DjtdvwvThBCQhW0SJU4FM6WY0-ot4m92M5K--1xtC0HDvhiy_Pe08xvCHlLYUuBtpe7rY37-y2D-gFiC9A-I-dUKLoRveLPn95dz87Iq5x3AFRyrl6SMwai423LzsndNZbiw69mMPahMaUJpiwJPzRLcJhyMcGt1XJ_nL1tHB5wivsZQ2lqpYkHTDbOq8KXXO2pNnR8TV6MZsr45vG-ID-_fvlxdbO5_X797erz7cYK1ZbNiA4Q21bKASRno5SgWM8ol9wo0ffQypGLYTCMDq4TaHpuOUjFDRfKdcgvyPtT7j7F3wvmomefLU6TCRiXrFUdvYbJrirZSWlTzDnhqPfJzyYdNQW9stQ7vbLUK0sNQleW1fTuMX4ZZnR_LU_wquDjSYB1yIPHpLP1GCw6n9AW7aL_f_6nf-x28sFbMz3gEfMuLilUfJrqzDTou3Wb6zIp1CMqpz-tQJoM</recordid><startdate>20100801</startdate><enddate>20100801</enddate><creator>Heng, Tracy SP</creator><creator>Chidgey, Ann P</creator><creator>Boyd, Richard L</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100801</creationdate><title>Getting back at nature: understanding thymic development and overcoming its atrophy</title><author>Heng, Tracy SP ; Chidgey, Ann P ; Boyd, Richard L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c476t-fed0ee6655b0532f55072921353a7499065f34bba21bd84ea93c30573a347d8e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aging - immunology</topic><topic>Aging - physiology</topic><topic>Animals</topic><topic>Antineoplastic Agents - toxicity</topic><topic>Atrophy - chemically induced</topic><topic>Epithelial Cells</topic><topic>Fibroblast Growth Factor 7 - pharmacology</topic><topic>fms-Like Tyrosine Kinase 3 - metabolism</topic><topic>Gonadal Steroid Hormones - antagonists & inhibitors</topic><topic>Growth Hormone - pharmacology</topic><topic>Humans</topic><topic>Insulin-Like Growth Factor I - pharmacology</topic><topic>Interleukin-7 - pharmacology</topic><topic>Internal Medicine</topic><topic>Medical Education</topic><topic>Membrane Proteins - pharmacology</topic><topic>Stem Cells - physiology</topic><topic>Stromal Cells</topic><topic>T-Lymphocytes - drug effects</topic><topic>T-Lymphocytes - immunology</topic><topic>T-Lymphocytes - physiology</topic><topic>Thymus Gland - drug effects</topic><topic>Thymus Gland - immunology</topic><topic>Thymus Gland - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Heng, Tracy SP</creatorcontrib><creatorcontrib>Chidgey, Ann P</creatorcontrib><creatorcontrib>Boyd, Richard L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current opinion in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Heng, Tracy SP</au><au>Chidgey, Ann P</au><au>Boyd, Richard L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Getting back at nature: understanding thymic development and overcoming its atrophy</atitle><jtitle>Current opinion in pharmacology</jtitle><addtitle>Curr Opin Pharmacol</addtitle><date>2010-08-01</date><risdate>2010</risdate><volume>10</volume><issue>4</issue><spage>425</spage><epage>433</epage><pages>425-433</pages><issn>1471-4892</issn><eissn>1471-4973</eissn><abstract>T cell development is a complex and tightly regulated process involving reciprocal interactions between the thymic stroma and differentiating thymocytes. Normal thymic function is critical for immunity and microenvironmental defects predispose to dysregulation in the T cell compartment. Thymic structure and function are also severely damaged by chemotherapy and pre-transplant conditioning. Furthermore, poor immune competence with ageing is closely linked to thymic atrophy. Overcoming such thymic defects would have immediate application in many diseases, especially the recovery of cancer patients from cytotoxic treatment. Reversing the thymus ageing process via inhibition of atrophic factors such as sex steroids or administration of thymopoietic growth factors is one possible approach. Moreover, it is becoming clear a common thymic epithelial progenitor exists, raising the possibility for de novo thymus generation using emerging stem cell and tissue engineering technologies. Achievement of this goal will open up many avenues for the application of thymus-based immune rejuvenation and manipulation.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>20483662</pmid><doi>10.1016/j.coph.2010.04.006</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1471-4892 |
ispartof | Current opinion in pharmacology, 2010-08, Vol.10 (4), p.425-433 |
issn | 1471-4892 1471-4973 |
language | eng |
recordid | cdi_proquest_miscellaneous_748935358 |
source | Elsevier |
subjects | Aging - immunology Aging - physiology Animals Antineoplastic Agents - toxicity Atrophy - chemically induced Epithelial Cells Fibroblast Growth Factor 7 - pharmacology fms-Like Tyrosine Kinase 3 - metabolism Gonadal Steroid Hormones - antagonists & inhibitors Growth Hormone - pharmacology Humans Insulin-Like Growth Factor I - pharmacology Interleukin-7 - pharmacology Internal Medicine Medical Education Membrane Proteins - pharmacology Stem Cells - physiology Stromal Cells T-Lymphocytes - drug effects T-Lymphocytes - immunology T-Lymphocytes - physiology Thymus Gland - drug effects Thymus Gland - immunology Thymus Gland - physiology |
title | Getting back at nature: understanding thymic development and overcoming its atrophy |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T12%3A52%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Getting%20back%20at%20nature:%20understanding%20thymic%20development%20and%20overcoming%20its%20atrophy&rft.jtitle=Current%20opinion%20in%20pharmacology&rft.au=Heng,%20Tracy%20SP&rft.date=2010-08-01&rft.volume=10&rft.issue=4&rft.spage=425&rft.epage=433&rft.pages=425-433&rft.issn=1471-4892&rft.eissn=1471-4973&rft_id=info:doi/10.1016/j.coph.2010.04.006&rft_dat=%3Cproquest_cross%3E748935358%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c476t-fed0ee6655b0532f55072921353a7499065f34bba21bd84ea93c30573a347d8e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=748935358&rft_id=info:pmid/20483662&rfr_iscdi=true |